Blood Proteins Patents (Class 435/69.6)
  • Patent number: 11359010
    Abstract: It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: June 14, 2022
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Philippe Tessier, Mélanie Tardif, Traian Sulea
  • Patent number: 11352445
    Abstract: Methods for preparing a recombinant protein from a bacterium are provided. The method includes constructing an expression vector including two promoters. Each of the two promoters attaches a secretion signal peptide to one polypeptide of a protein. The protein attached with the two promoters and secretion signal peptides is then cloned into the expression vector to provide a recombinant expression plasmid. The recombinant expression plasmid is transformed into a host cell. A fermentation process is performed to grow the host cell and to induce an expression to synthesize polypeptides in the host cell and to transport the polypeptides to an outside of a cytoplasm of the host cell, such that the polypeptides are released in a soluble form in a growth medium of the host cell. The polypeptides are assembled into a three-dimensional structure of the protein. The protein is captured from the growth medium.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: June 7, 2022
    Assignee: JECHO LABORATORIES INC.
    Inventors: Jianwei Zhu, Cedric Cagliero, Andrew Burnette, Yueqing Xie, Hua Jiang, Huili Lu, Manyu Luo
  • Patent number: 11345742
    Abstract: The present disclosure provides coronavirus S1-fragment specific binding moieties comprising Type II VNAR domains, VNAR antibodies, methods of using those moieties and antibodies to treat COVID-19. In some embodiments, a VNAR antibody, originally selected from a phage display library as a VNAR clone using S1fragments from the SARS-CoV-2 Wuhan strain, are also effective at specifically binding to and/or neutralizing SARS-CoV-2 and certain SARS-CoV-2 mutants.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: May 31, 2022
    Assignee: Ossianix, Inc.
    Inventors: Aziz Gauhar, Cyril V. Privezentzev, Pawel Stocki, Julia Lynn Rutkowski
  • Patent number: 11345920
    Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3?-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule as a medicament, as a vaccine or in gene therapy.
    Type: Grant
    Filed: December 5, 2021
    Date of Patent: May 31, 2022
    Assignee: CureVac AG
    Inventors: Andreas Thess, Thomas Schlake, Stefanie Grund
  • Patent number: 11339226
    Abstract: The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 24, 2022
    Assignee: Katholieke Universiteit Leuven
    Inventors: Karen Vanhoorelbeke, Shannen F. Deconinck, An-Sofie Schelpe
  • Patent number: 11326153
    Abstract: The present invention relates to alpha-amylase variants comprising a substitution at a position corresponding to position 188 and at least one further substitution at a position corresponding to position 242 or 279 or 275 of SEQ ID NO: 1, in particular one or more combinations of substitutions selected from the group consisting of E188P+S242Y, E188P+S242F, E188P+S242H, E188P+S242W, E188P+S242P, E188P+S242I, E188P+S242T, E188P+S242L, E188P+K279W, E188P+K279Y, E188P+K279F, E188P+K279H, E188P+K279I, E188P+K279L, E188P+K279D, E188P+K279M, E188P+K279S, E188P+K279T E188P+K279N, E188P+K279Q, E188P+K279V, E188P+K279A, E188P+N275F, E188P+N275Y, E188P+N275W, and E188P+N275H, wherein the variant has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to a parent alpha amylase selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: May 10, 2022
    Assignee: NOVOZYMES A/S
    Inventors: Carsten Andersen, Vasudeva Prahlada Rao, Rakhi Saikia, Vivek Srivastava, Kendra Darlene Stallings
  • Patent number: 11319373
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: May 3, 2022
    Assignee: Alector LLC
    Inventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
  • Patent number: 11292843
    Abstract: The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a N detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 5, 2022
    Assignee: Genentech, Inc.
    Inventors: Doris Kim, Terence Wong, Anan Chuntharapai, Cherie Louise Green
  • Patent number: 11292850
    Abstract: Provided herein, inter alia, are isolated, humanized antibodies that bind an extracellular domain of a human SIRP-? polypeptide. Also provided are polynucleotides, vectors, host cells, and methods of production and use related thereto.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 5, 2022
    Assignee: ALX ONCOLOGY INC.
    Inventors: Jaume Pons, Bang Janet Sim, Hong Wan, Tracy Chia-Chien Kuo
  • Patent number: 11261234
    Abstract: In one aspect, present invention provides a recombinant mutant human factor VIII having increased expression and/or secretion as compared to wild-type factor VIII. In certain embodiments, the recombinant factor VIII includes one or more amino acid substitution(s) selected from the group consisting of I86, Y105, A108, D115, Q117, F129, G132, H134, M147 and L152. In other aspects, the present invention provides FVIII encoding nucleic acids, FVIII-expression vectors, as well as methods of using the modified FVIII genes in the treatment of FVIII deficiencies, such as hemophilia A.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 1, 2022
    Assignee: IVYGEN CORPORATION
    Inventors: Weidong Xiao, Wenjing Cao, Biao Dong
  • Patent number: 11255865
    Abstract: Disclosed herein are antibodies that specifically bind human erythroferrone and assay methods for detecting and/or measuring human erythroferrone, analogs of human erythroferrone, and fragments thereof. Specifically, the methods comprising using an antibody as a capture reagent and an antibody as a detection reagent for detecting or measuring a detectable label of the at least one detection reagent bound to the erythroferrone polypeptide that is bound to the capture reagent. Further disclosed are the sequences of antibodies.
    Type: Grant
    Filed: May 28, 2018
    Date of Patent: February 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Tomas Ganz, Elizabeta Nemeth, Leon Kautz, Chun-Ling Jung
  • Patent number: 11242400
    Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: February 8, 2022
    Assignee: Aptevo Research and Development LLC
    Inventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
  • Patent number: 11203634
    Abstract: The present disclosure relates to, inter alia, a method of treating age-related macular degeneration (AMD) in a patient, comprising administering an effective amount of a C5 inhibitor or a C5a inhibitor.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: December 21, 2021
    Assignee: ALEXION PHARMACEUTICALS, INC.
    Inventors: Yi Wang, Barbel Rohrer
  • Patent number: 11198730
    Abstract: The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: December 14, 2021
    Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido University
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
  • Patent number: 11186833
    Abstract: The present invention relates to polypeptide variants having alpha-amylase activity and an improved property, such as improved specific activity, as compared to the parent polypeptide. The invention further relates to use of the polypeptide variants, compositions comprising the polypeptide variants, and methods of producing the polypeptide variants.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: November 30, 2021
    Assignee: NOVOZYMES A/S
    Inventor: Carsten Andersen
  • Patent number: 11180745
    Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: November 23, 2021
    Assignee: Novozymes A/S
    Inventors: Carsten Andersen, Signe E. Larsen, Esben Peter Friis, Pernille Ollendorff Micheelsen, Anders Viksoee-Nielsen, Randy Deinhammer, Xinyu Shen
  • Patent number: 11180544
    Abstract: A method of producing an antibody fragment for a target antigen includes administering an immunizing mixture containing the target antigen to a cartilaginous fish for at least two times; collecting a blood sample from the cartilaginous fish; extracting RNAs from the blood sample; subjecting said RNAs to reverse transcription to obtain a complementary DNA, and optionally amplifying the cDNA to obtain a mixture of amplified cDNAs followed by purification. Also covered are methods of producing an antibody fragment from a shark; antibody fragments obtained from the method; a kit comprising antibody fragments; and methods of determining the presence and/or amount of a target antigen in a sample.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: November 23, 2021
    Assignee: City University of Hong Kong
    Inventors: Jiahai Shi, Lai Leo Chan, Likun Wei, Limin Feng
  • Patent number: 11161910
    Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 2, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Jose A. Halperin, Michael Chorev
  • Patent number: 11155638
    Abstract: The present disclosure relates to antibodies that bind human chitinase-3-like protein 1 (CHI3L1) and uses thereof. In aspects, the antibodies are useful in compositions and methods for detecting and/or treating nonalcoholic steatohepatitis (NAFLD) or nonalcoholic fatty liver disease (NASH) in a subject, as well as subsequent complications of untreated progression in the liver of a subject, such as liver cirrhosis and/or a hepatocellular carcinoma.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: October 26, 2021
    Assignee: RHODE ISLAND HOSPITAL
    Inventors: Jack R. Wands, Rolf I. Carlson
  • Patent number: 11155637
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: October 26, 2021
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Patent number: 11124572
    Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 21, 2021
    Assignee: QLSF BIOTHERAPEUTICS INC.
    Inventor: Shihao Chen
  • Patent number: 11118208
    Abstract: The present invention relates to methods and compositions for modulating glycosylation profile, such as the galactosylation profile, of recombinant proteins expressed by mammalian host cells during the cell culture process by supplementing cell culture media with a peracetyl galactose.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: September 14, 2021
    Assignee: ARES TRADING S.A.
    Inventors: Martin Jordan, Gabrielle Leclercq, Jonathan Souquet, Herve Broly, David Bruhlmann
  • Patent number: 11098132
    Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: August 24, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dirk Voelkel, Robert Pachlinger, Hanspeter Rottensteiner, Alfred Weber, Andrea Engelmaier
  • Patent number: 11078276
    Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: August 3, 2021
    Assignee: Nepenthe Bioscience LLC
    Inventors: James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
  • Patent number: 11033638
    Abstract: The invention relates to a viral expression construct and related viral vector and composition and to their use wherein the construct and vector comprise elements a) and b): a) a nucleotide sequence encoding an insulin operably linked to a first promoter, b) a nucleotide sequence encoding a glucokinase operably linked to a second promoter and the viral expression construct and related viral vector comprise at least one of elements c), d) and e): c) the first and the second promoters are positioned in reverse orientation within the expression construct, d) the first and the second promoters are positioned in reverse orientation within the expression construct and are located adjacent to each other and e) the first promoter is a CMV promoter, preferably a mini CMV promoter.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: June 15, 2021
    Assignee: UNIVERSITÄT AUTONOMA DE BARCELONA
    Inventors: Fatima Bosch Tubert, Miguel Garcia Martinez, Veronica Jiménez Cenzano, Virginia Haurigot Mendonça
  • Patent number: 11029303
    Abstract: The invention is directed to antibody compositions that specifically bind to polycyclic aromatic hydrocarbons (PAHs) and kits encompassing the same.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: June 8, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Diane Blake, Yue Sun
  • Patent number: 11008389
    Abstract: Uses of a dual V region antibody-like protein or a fragment of a dual V region antibody-like region.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 18, 2021
    Assignee: SANOFI
    Inventors: Florent C. Bender, Danxi Li, Anne Minnich, Amirtha Naadimuthu, Ercole Rao, Brian N. Swanson, Lei Tang, Haixin Yu, Otmane Boussif, Sophie Carayon
  • Patent number: 10981975
    Abstract: The present invention describes a simple purification process for recombinant human serum albumin. The process results in highly purified protein with limited number of purification steps. The broth containing human albumin is clarified by centrifugation and microfiltration, diafiltered and captured by cation exchange chromatography by a process that allows 140-230 mg of albumin to be captured per ml of resin. Product related impurities are removed by hydrophobic interaction chromatography, optimised to allow 87-97% recovery in flow through mode. The final series of processes are so combined that there is easy transition from one step to the next with minimal interventions and adjustments. The entire process of purification is completed within two days from harvest to final product. Thus a cost-effective process with improved recovery of protein at each step is developed. The purified human serum albumin is analyzed for purity and shows physicochemical characteristics that are similar to standard albumin.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: April 20, 2021
    Assignee: SHILPA BIOLOGICALS PVT. LTD.
    Inventor: Rajyashri Ramakrishna Karur
  • Patent number: 10973881
    Abstract: The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: April 13, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Sung Youb Jung, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi
  • Patent number: 10870695
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: December 22, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Patent number: 10844135
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: November 24, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blattler
  • Patent number: 10829565
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 10, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Christopher John Le Page, Razwan Hanif
  • Patent number: 10759861
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 1, 2020
    Assignee: Ablexis, LLC
    Inventors: John Lippincott, Dana Duey
  • Patent number: 10723801
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: July 28, 2020
    Assignee: Ablexis, LLC
    Inventors: John Lippincott, Dana Duey
  • Patent number: 10712345
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 14, 2020
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Patent number: 10689630
    Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein an alpha-amylase and a thermostable hemicellulase is present and/or added during liquefaction. The invention also relates to compositions suitable for use in processes of the invention.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 23, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Zhengfang Kang, Christie Lynn Strahler, James Ron Huffman, Kristian Bertel Rømer M. Krogh
  • Patent number: 10640575
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 5, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Patent number: 10590457
    Abstract: The present invention relates to new methods and processes for culturing mammalian cells with the addition of phenolic antioxidants. Performance of the cell culturing methods and processes in their various aspects result in a higher viable cell density and higher protein titer.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 17, 2020
    Assignee: BRISTOL MYERS-SQUIBB COMPANY
    Inventors: Jun Tian, Jianlin Xu, Qin He
  • Patent number: 10557160
    Abstract: Recombinant bacterial cells are provided that comprise a stable non-canonical amino acid translation pathway. In some aspects, the bacteria comprise nucleic acids encoding a non-canonical amino acid translation pathway (e.g., a tRNA for incorporation of a non-canonical amino acid, such selenocysteine); a marker polypeptide that includes the non-canonical amino acid. Recombinant tRNA and selection marker coding sequences are likewise provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 11, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew D. Ellington, Ross Thyer
  • Patent number: 10472411
    Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: November 12, 2019
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Hong-Sen Chen, Ing-Chien Chen, Chao-Ping Tung, Shin-Chen Hou, Chung-Ming Yu, Chi-Kai Yang, Yi-Kai Chiu
  • Patent number: 10407484
    Abstract: The present disclosure relates to compositions and methods for modulating T-cell mediated immune response in a subject in need thereof. The method includes administering to the subject an effective amount of a CD112R protein, a fusion polypeptide, a complex including CD112R and a second protein, or an anti-CD112R antibody of the present disclosure.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 10, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Yuwen Zhu, Barish H. Edil, Richard D. Schulick, Alessandro Paniccia, Michelle Koenig, Alexander C. Schulick
  • Patent number: 10377812
    Abstract: The present invention describes a simple purification process for recombinant human serum albumin. The process results in highly purified protein with limited number of purification steps. The broth containing human albumin is clarified by centrifugation and microfiltration, diafiltered and captured by cation exchange chromatography by a process that allows 140-230 mg of albumin to be captured per ml of resin. Product related impurities are removed by hydrophobic interaction chromatography, optimized to allow 87-97% recovery in flow through mode. The final series of processes are so combined that there is easy transition from one step to the next with minimal interventions and adjustments. The entire process of purification is completed within two days from harvest to final product. Thus a cost-effective process with improved recovery of protein at each step is developed. The purified human serum albumin is analyzed for purity and shows physicochemical characteristics that are similar to standard albumin.
    Type: Grant
    Filed: January 1, 2016
    Date of Patent: August 13, 2019
    Assignee: NAVYA BIOLOGICALS PVT LTD
    Inventor: Rajyashri Ramakrishna Karur
  • Patent number: 10358479
    Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: July 23, 2019
    Assignee: ZYMEWORKS INC.
    Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
  • Patent number: 10336816
    Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: July 2, 2019
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Hong-Sen Chen, Ing-Chien Chen, Chao-Ping Tung, Shin-Chen Hou, Chung-Ming Yu, Chi-Kai Yang, Yi-Kai Chiu
  • Patent number: 10323287
    Abstract: This invention relates in part to plant breeding and herbicide tolerant plants. This invention includes a novel aad-1 transformation event in corn plants comprising a polynucleotide sequence, as described herein, inserted into a specific site within the genome of a corn cell. In some embodiments, said event/polynucleotide sequence can be “stacked” with other traits, including, for example, other herbicide tolerance gene(s) and/or insect-inhibitory proteins. Additionally, the subject invention provides assays for detecting the presence of the subject event in a sample (of corn grain, for example). The assays can be based on the DNA sequence of the recombinant construct, inserted into the corn genome, and on the genomic sequences flanking the insertion site. Kits and conditions useful in conducting the assays are also provided.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: June 18, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Yunxing Cory Cui, Jill Bryan, Donald Maum, Greg Gilles, Terry Wright, Jennifer Hamilton, Nicole Arnold, Nathan VanOpdorp, Tina Kaiser, Ning Zhou
  • Patent number: 10280211
    Abstract: The present invention relates to methods for screening and producing polypeptides that immunospecifically bind to an antigen, which: polypeptides comprise binding domains that are derived from rabbit immunoglobulin. Using rabbit antibody heavy-chain or light-chain scaffolds, the methods of the invention allow identification of novel CDR loops and framework regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production research tools or therapeutic immunospecific polypeptides, including single domain immunospecific polypeptides, i.e., comprising one of a VH or VL domain.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: May 7, 2019
    Assignee: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA
    Inventors: João Manuel Braz Goncalves, Frederico Nuno Castanheira Aires Da Silva
  • Patent number: 10267714
    Abstract: The present invention provides an aminoalcohol together with, as necessary, at least one selected from the group consisting of: at least one compound selected from the group consisting of urea and a urea derivative; a nonionic detergent; and sucrose to provide a biological material having an excellent light-transmitting property. The present invention provides a technique that allows a high-throughput observation of gene expression/localization or cell morphology in tissue at an whole-tissue level.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: April 23, 2019
    Assignee: RIKEN
    Inventors: Etsuo Susaki, Hiroki Ueda, Kazuki Tainaka
  • Patent number: 10247745
    Abstract: The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol that can enable full automation and reduced sample preparation time relative to current methods of glycoanalysis. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method without requiring time-consuming sample preparation steps such as centrifugation or vacuum-centrifugation.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: April 2, 2019
    Assignee: Beckman Coulter, Inc.
    Inventors: Andras Guttman, Clarence Lew, Marton Szigeti, Csaba Varadi
  • Patent number: 10247729
    Abstract: Disclosed are methods and kits for early detection of antigen exposure through the presence or absence of antigen-specific antibodies.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: April 2, 2019
    Assignee: MICROBPLEX, INC.
    Inventors: Frances Eun-Hyung Lee, John L. Daiss
  • Patent number: 10221403
    Abstract: The present invention provides a method of preparing zearalenone hydrolase, including the step of culturing a yeast cell carrying a gene encoding a zearalenone hydrolase in a medium to express a protein of the zearalenone hydrolase, wherein the medium contains 20 to 25% molasses by weight. This method provides a new strategy to efficiently prepare zearalenone hydrolase at low expenses.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 5, 2019
    Assignee: LIFE RAINBOW BIOTECH CO., LTD.
    Inventors: Ching-Kuo Yang, Yu-Hsiang Yu, Ya-Chieh Huang, Rou-Wan Liao